RE:Anyone have guess on where we go from here?Company has $40m in cash. While 2/3 of Advisory Comm said no, 1/3 said yes and were quite enthusiastic. Will be very difficult to reject the drug outright esp on fast track. If they do then the drug is likely dead in the water and never to be developed. Even the negative opinions almost to a person wanted to approve the drug and or thought it would do little or no harm. FDA will IMO approve for very limited pop with a number of studies to be completed, after all their single biggest worry is safety and this drug is basically safe, efficacy will be teased out and reinforced with further sensible studies now that that is clear, like 2 arm against BCG. Placebo is not an option.